Skip to main content
. 2022 Sep 1;14(19):1403–1416. doi: 10.4155/fmc-2022-0149

Figure 4. . Chemical structures of protease-targeted chimera molecules as degraders of ALK/AR/BCR-ABL for the treatment of cancer (blue indicates the E3 ligase ligand cereblon; red indicates the target inhibitor).

Figure 4. 

ALK: Anaplastic lymphoma kinase; AR: Androgen receptor.